EkoSonic™ Endovascular System

Ultrasonic Technology

Control Unit

Clinical Evidence
EKOS™ Ultrasound Guided Catheter directed thrombolysis for deep vein thrombosis and pulmonary embolism.
EKOSONIC® The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
play icon
See how the EKOS device mechanism of action works.
The EkoSonic catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.
EKOS™ Ultrasound Guided Catheter directed thrombolysis for deep vein thrombosis and pulmonary embolism.
EKOSONIC® The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
play icon
See how the EKOS device mechanism of action works.
The EkoSonic catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.
EKOS™ Ultrasound Guided Catheter directed thrombolysis for deep vein thrombosis and pulmonary embolism.
EKOSONIC® The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
See how the EKOS device mechanism of action works.
The EkoSonic catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.

The EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT) and peripheral arterial occlusion (PAO).

Key Resources

EkoSonic Indications, Safety, and Warnings
Sign-Up for Product Updates

Product Description

EKOS therapy is a minimally invasive system for dissolving thrombus. The ultrasonic core generates an acoustic field which greatly accelerates lytic dispersion by driving the drug deeper into the clot and unwinding the fibrin to expose plasminogen receptor sites. 

Acoustic Pulse Thrombolysis™

  • Speeds time-to-clot dissolution.
  • Results in quality clinical outcomes.
  • Increases clot removal and enhances clinical improvement compared to either standard catheter-directed drug therapy or thrombectomy.1,2
  • Requires significantly shorter treatment times compared to standard CDT.3
  1. Lin, P., et al., Vasc, Vol. 17, Suppl. 3, 2009, S137-S147.
  2. Lin., P., et al., Perspectives in Vasc Surg and Endo Ther, 2010, 22(3):152-163.
  3. Litzendorf, M., et al., SVS 2011 Abstract RR20.

Targets the Thrombus Safely

  • Lowers the risk of bleeding and other complications.14,1
  • Dissolves clots without damaging vessels, valves or walls.9

More Effective Drug Delivery

  • Reduces dosage requirements by as much as 68% compared to standard, catheter-directed drug therapy.1
  • Requires up to 4x less drug dosage than traditional systemic delivery.4,5
  • Reduces RV/LV ratio with as little as 8mg total tPA used in combination with EKOS™ therapy.19

Superior Clot Clearance3,7

  • 48% greater drug absorption within 1 hour.16
  • 84% greater drug absorption within 2 hours. 16
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2020 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. 93-204   
Top